Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Neoadjuvant Chemotherapy in Early TNBC
NCT04582955Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tucidinostat in triple-negative breast cancer (TNBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Pathologic Complete Response Rate at 1 year. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04582955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582955.